C-reactive protein as the indicator of severity in ovarian hyperstimulation syndrome

References

• Delbaere A, Smits G, Olatunbosun O. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod 2004;19:486–489.
   PubMed Web of Science ®Google Scholar
• Jakimiuk AJ, Fritz A, Grzybowski W, Walecka I, Lewandowski P. Diagnosing and management of iatrogenic moderate and severe ovarian hyperstymulation syndrome (OHSS) in clinical material. Fol Histochem Cytobiol 2007;45(Suppl 1):S105–S108.
   Google Scholar
• Jakimiuk AJ, Grzybowski W, Zakrzewski J, Lewandowski P, Kozioł K. The ovarian hyperstymulation syndrome – diagnosing criteria, management procedures. Ginekol Pol 2006;77:885–892.
   Google Scholar
• Taher BM, Ghariabeh RA, Jarrah NS. Spontaneous ovarian hyperstimulation syndrome caused by hypothyroidism in adult. Eur J Obstet Gynaecol Reprod Biol 2004;112:107–109.
   PubMed Web of Science ®Google Scholar
• Al-Ramahi M. Severe OHSS: decreasing the risk of severe ovarian hyperstimulation syndrome. Hum Reprod 1999;14:2421–2422.
   PubMedGoogle Scholar
• Fluker MR, Copeland JE, Yuzpe AA. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril 2000;73:38–45.
   PubMedGoogle Scholar
• Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod 2003;9:275–289.
   Google Scholar
• Isik AZ, Vicdan K. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. Eur J Obstet Gynaecol Reprod Biol 2001;97:208–212.
   Google Scholar
• Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995;27:334–346.
   Google Scholar
• Semba S, Moriya T, Youssef EM, Sasano H. An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. Pathol Int 2000;50:549–552.
   PubMed Web of Science ®Google Scholar
• Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynaecol 1998;159:210–215.
   Google Scholar
• MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992;7:597–600.
   PubMedGoogle Scholar
• Buyalos RP, Lee CT. Polycystic ovarian syndrome: pathophysiology and outcome with in vitro fertilization. Fertil Steril 1996;65:1–10.
   PubMed Web of Science ®Google Scholar
• Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E. Ovarian hyperstimulation syndrome following D-Trp-6 luteinising hormone releasing hormone microcapsules and menotrophin for in vitro fertilization. Fertil Steril 1998;50:912–916.
   Google Scholar
• Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, Englert Y, Delbeke L, Darcis L, Gordts S, et al The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. Clinical and biological features. Hum Reprod 1993;8:1353–1360.
   PubMed Web of Science ®Google Scholar
• Golan A, Ron-El R, Soffer Y, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynaecol 1989;44:430–440.
   Google Scholar
• Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999;71:645–651.
   PubMed Web of Science ®Google Scholar
• Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 2001;75:1228–1230.
   PubMedGoogle Scholar
• Gokmen O, Ugur M, Ekin M. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization program: a prospective randomized placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 2001;96:187–192.
   PubMed Web of Science ®Google Scholar
• Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989;51:791–795.
   PubMed Web of Science ®Google Scholar
• D'Angelo A, Amso N. ‘Coasting’ (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002;(3): CD002811.
   Google Scholar
• Delvigne A, Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int J Fertil Women's Med 2002;7(5):211–226.
   Google Scholar
• Enskog A, Henriksson M, Unander M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808–814.
   PubMed Web of Science ®Google Scholar
• Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000;74:429–438.
   PubMed Web of Science ®Google Scholar
• Goldsman MP, Pedram A, Dominguez CE. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995;63:268–272.
   PubMed Web of Science ®Google Scholar
• Levin ER, Rosen GF, Cassidenti DL. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978–1985.
   PubMedGoogle Scholar
• McClure N, Healy DL, Rogers PA. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235–236.
   PubMed Web of Science ®Google Scholar
• Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril 1999;71:562–563.
   PubMed Web of Science ®Google Scholar
• Pellicer A, Albert C, Mercader A. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71:482–489.
   PubMed Web of Science ®Google Scholar
• Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 2002;12:111–116.
   Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2004;82(Suppl. 1):81–86.
   Google Scholar
• Abramov Y, Elchalal U, Schenker JG. Severe OHSS: an ‘epidemic’ of severe OHSS: a price we have to pay? Hum Reprod 1999;14:2181–2185.
   PubMed Web of Science ®Google Scholar
• Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990;53:502–509.
   PubMed Web of Science ®Google Scholar
• Ablij HC, Meinders AE. C-reactive protein: history and revival. Eur J Intern Med 2002;13:412–422.
   PubMedGoogle Scholar
• Gewurz H, Mold C, Siegel J, Fiedel B. C-reactive protein and the acute phase response. Adv Int Med 1982;27:345–372.
   PubMedGoogle Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805–1812.
   PubMed Web of Science ®Google Scholar
• Silvestri A, Gebara O, Vitale C. Increased levels of c-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:165–169.
   Google Scholar
• Kluft C, de Maat MPM. Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low-levels of C-reactive protein. Vasc Pharmacol 2002;39:99–104.
   Google Scholar
• Levin I, Gamsu R, Pauzner D, Rogowski O, Shapira I, Maslovitz S, Almog B. Elevated levels of c-reactive protein in ovarian hyperstimulation syndrome: an unrecognized potential hazard. BJOG 2005;112:952–955.
   PubMed Web of Science ®Google Scholar
• Orvieto R. Controlled ovarian hyperstimulation – an inflammatory state. J Soc Gynaecol Invest 2004;11:424–426.
   Google Scholar
• Orvieto R, Zagatsky I, Yulzari-Roll V, La Marca A, Fisch B. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecol Endocrinol 2006;22:437–440.
   Web of Science ®Google Scholar
• Almagor M, Hazav A, Yaffe H. The levels of C-reactive protein in woman treated by IVF. Hum Reprod 2004;19:104–106.
   PubMed Web of Science ®Google Scholar
• Barak V, Elchalal U, Edelstein M. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 2004;82:415–420.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Chen R, Ashkenazi J, Ben-Harush A, Bar J, Fisch B. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle. Hum Reprod 2004;19:357–359.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Leites T, Abir R, Bar J, Yoeli R, Feldberg D, Fisch B. Interleukin-2 production in whole blood cell cultures of women undergoing controlled ovarian hyperstimulation for assisted reproduction technology cycles. Am J Reprod Immunol 2003;50:220–223.
   Google Scholar